Skip to main content
WPD Pharmaceuticals Inc. logo

WPD Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · WBIO ISIN · CA92941F2044 LEI · 549300YZKU39UPMSYY11 CSE Financial and insurance activities
Open in API
Filings indexed 162 across all filing types
Latest filing 2025-01-09 Share Issue/Capital Cha…
Country CA Canada
Listing CSE WBIO

About WPD Pharmaceuticals Inc.

https://www.wpdpharmaceuticals.com/

WPD Pharmaceuticals Inc. is a biotechnology company that currently maintains no active business operations. Its sole asset is a minority equity stake (approximately 7%) in its former subsidiary, WPD Pharmaceuticals Sp. zo.o., following a restructuring in November 2022. The Polish entity, which WPD Pharmaceuticals Inc. holds shares in, is a biotechnology research and development company focused on oncology. Its core activities involve the research and development of medicinal products, including biological compounds and small molecules, primarily targeting targeted therapy for brain glioma and other central nervous system cancers.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a Material Change Report (Form 51-102F3) announcing a consolidation of common shares (one post-consolidation share for every twenty-five pre-consolidation shares) and the record date, which is a corporate action altering share capital. This falls under the category of share capital changes (stock splits/consolidations).
2025-01-09 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a corporate press release announcing the consolidation (reverse split) of common shares, describing the record date, ratio, fractional share treatment, and issuance of new certificates. This is a change in capital structure (share consolidation), which falls under the Share Issue/Capital Change category (SHA).
2024-12-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Form 52-109FV2 “Certification of Interim Filings” by the CEO, confirming review and fair presentation of an interim financial report and interim MD&A for the period ended September 30, 2024. It is not the interim report itself, nor an announcement of dividend, share issue, or management changes, but rather a regulatory compliance certificate. There is no specific category for a certification form, so it falls into the fallback “Regulatory Filings” category (RNS).
2024-12-12 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a CFO’s certification under Canadian NI 52-109 for the interim filings (interim financial report and interim MD&A) for the period ended September 30, 2024. It is not the interim report itself but a regulatory compliance certificate. It does not present financials or MD&A content but provides the required attestations. This falls under general regulatory filings (fallback category) rather than an actual Interim Report or Audit Report.
2024-12-12 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion & Analysis” for the nine months ended September 30, 2024 and 2023, providing management’s assessment, analysis of operations, financial condition, quarterly results, and forward-looking statements. This matches the definition for “Management Reports (MDA)” – management’s detailed explanation of financial results, business trends, and outlook – rather than an actual interim financial statement or merely an announcement. Thus the correct classification is MDA.
2024-12-12 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of 'Condensed Interim Financial Statements' for WPD Pharmaceuticals Inc. for the three and nine months ended September 30, 2024. It includes the Statement of Financial Position, Statement of Income/Loss, Statement of Cash Flows, Statement of Changes in Shareholders' Deficiency, and detailed Notes to the Financial Statements. This content constitutes a formal interim financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.